Janux Therapeutics, Inc. (NASDAQ:JANX) Stock Has Consensus Target Price of $36.46

Posted by on Oct 12th, 2026

Shares of Janux Therapeutics, Inc. (NASDAQ:JANX – Get Free Report) have earned a consensus rating of “Moderate Buy” from the fifteen brokerages that are presently covering the firm, Marketbeat Ratings reports. Two research analysts have rated the stock with a sell recommendation, two have assigned a hold recommendation, ten have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month price target among analysts that have covered the stock in the last year is $36.46.

A number of equities research analysts have weighed in on the company. Stifel Nicolaus set a $35.00 target price on Janux Therapeutics in a research report on Friday, August 7th. Wolfe Research upgraded Janux Therapeutics from a “peer perform” rating to an “outperform” rating and set a $23.00 target price for the company in a report on Monday, August 24th. TD Cowen raised Janux Therapeutics to a “strong-buy” rating in a research report on Monday, August 24th. Truist Financial reissued a “buy” rating and set a $26.00 price target (down from $80.00) on shares of Janux Therapeutics in a research report on Thursday, June 25th. Finally, Guggenheim cut their price target on Janux Therapeutics from $58.00 to $55.00 and set a “buy” rating on the stock in a research note on Friday, August 7th.

Read Our Latest Report on JANX

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in JANX. GAMMA Investing LLC increased its position in Janux Therapeutics by 67.4% during the 3rd quarter. GAMMA Investing LLC now owns 1,642 shares of the company’s stock valued at $28,000 after purchasing an additional 661 shares during the period. Versant Capital Management Inc raised its holdings in shares of Janux Therapeutics by 42.8% in the 2nd quarter. Versant Capital Management Inc now owns 2,615 shares of the company’s stock valued at $40,000 after purchasing an additional 784 shares in the last quarter. Quantinno Capital Management LP lifted its position in shares of Janux Therapeutics by 7.6% in the 1st quarter. Quantinno Capital Management LP now owns 26,064 shares of the company’s stock worth $362,000 after purchasing an additional 1,846 shares during the period. Caitong International Asset Management Co. Ltd purchased a new stake in shares of Janux Therapeutics in the 4th quarter worth approximately $51,000. Finally, Raiffeisen Bank International AG lifted its position in shares of Janux Therapeutics by 9.1% in the 2nd quarter. Raiffeisen Bank International AG now owns 60,000 shares of the company’s stock worth $920,000 after purchasing an additional 5,000 shares during the period. 75.39% of the stock is currently owned by institutional investors.

Janux Therapeutics Stock Performance

Janux Therapeutics stock opened at $18.39 on Friday. The company has a 50 day moving average price of $17.42 and a 200-day moving average price of $15.69. Janux Therapeutics has a fifty-two week low of $12.12 and a fifty-two week high of $35.34. The company has a market capitalization of $1.12 billion, a PE ratio of -11.21 and a beta of 2.40.

Janux Therapeutics (NASDAQ:JANX – Get Free Report) last announced its quarterly earnings results on Thursday, August 6th. The company reported ($0.35) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.25) by ($0.10). The company had revenue of $10.27 million during the quarter, compared to analysts’ expectations of $19.07 million. On average, analysts forecast that Janux Therapeutics will post -1.70 earnings per share for the current year.

Janux Therapeutics Company Profile

(Get Free Report)

Janux Therapeutics, Inc is a clinical-stage biopharmaceutical company based in San Diego, California, developing cancer immunotherapies designed to activate the immune system selectively within the tumor microenvironment. The company’s technology is intended to direct T cells toward cancer cells while limiting activation in healthy tissues.

Janux’s core technology platform, known as TRACTr, uses conditionally activated T-cell engager molecules designed to remain masked in circulation and become activated by proteases that are more prevalent in tumors.

Featured Stories

Analyst Recommendations for Janux Therapeutics (NASDAQ:JANX)

Receive News & Ratings for Janux Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Janux Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.